The rising interest in GLP-1 agonists for diabetes has led to a discussion about application forms : patches versus tablets . Usually , GLP-1 drugs were solely available in oral form, but the introduction of patches presents a different way. Transdermal systems might suit individuals with challenges with pills , those desiring to avoid first-pass l